新闻列表

FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'

2023-05-22


FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'

On May 19, 2023, the FDA approved Beremagene Geperpavec (B-VEC), a topical gene therapy based on the herpes simplex virus type 1 (HSV-1) developed by Krystal Biotech, under the trade name Vyjuvke. For the treatment of wounds in patients 6 months of age and older with malnourished epidermolysis bullosa (DEB) with COL7A1 gene mutation. Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disease caused by mutation of COL7A1 gene, which codes type VII collagen (C7). The patient is prone to skin bullosa and blood bullosa. These patients are also known as "butterfly babies", describing their skin as fragile as a butterfly that breaks at the touch. It is one of the most painful diseases in the world, and sufferers are prone to infection, skin cancer and even death.

上一页: FDA批准首个可重复给药基因疗法,每年63万美元,治疗“最痛苦疾病”

下一页: 患者年出血率降低71%,辉瑞血友病基因疗法上市申请获FDA受理